Mini Review ARTICLE
Clinical Implications and Impact of Discovery of the Thyroid Hormone Receptor on Integrin αvβ3 - A Review
- 1Cleveland Clinic, United States
Hypothyroidism has been reported to improve survival in cancer patients but only recently has the putative mechanism been identified as a receptor for thyroxine and tri-iodothyronine on integrin αvβ3. Recognition of divergence of action of the pro-oncogenic L-thyroxine (T4) from pro-metabolic 3,5,3’-triiodo-L-thyronine (T3) has enabled clinical implementation whereby exogenous T3 may replace exogenous (or endogenous) T4 to maintain clinical euthyroid hypothyroxinemia that results in significantly better survival in advanced cancer patients without the morbidity of clinical hypothyroidism.
Keywords: Hypothyroidism, Cancer, L-thyroxine (L-T4), Integrin αvβ3, Thyroid hormone receptor (TR), euthyroid hypothyroxinemia
Received: 13 May 2019;
Accepted: 02 Aug 2019.
Edited by:Sandra Incerpi, Roma Tre University, Italy
Reviewed by:Hynda K. Kleinman, School of Medicine and Health Sciences, George Washington University, United States
Roberto De Luca, Beth Israel Deaconess Medical Center, Harvard Medical School, United States
Copyright: © 2019 Hercbergs. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Aleck Hercbergs, Cleveland Clinic, Cleveland, Ohio, United States, firstname.lastname@example.org